This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064203%3A_____%2F12%3A8135%21RIV13-MZ0-00064203/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064203%3A_____%2F12%3A8135%21RIV13-MZ0-00064203
rdf:type
skos:Concept n14:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1007/s00345-012-0910-5
dcterms:description
To determine whether the number of lymph nodes (LNs) examined is associated with outcomes in patients without nodal metastasis after radical cystectomy (RC). We retrospectively analyzed data from 4,188 patients treated at 12 centers with RC and pelvic lymphadenectomy without neo-adjuvant chemotherapy for urothelial carcinoma of the bladder (UCB). Outcomes of patients without LN metastasis (n = 3,088) were examined according to the LN yield analyzed as continuous variable, tertiles, and using the cutoffs of a parts per thousand yen9 and a parts per thousand yen20. The median nodal yield was 18 (range 1-123; IQR:20). A total of 2591 (84 %) and 1445 (47 %) patients had a LN yield a parts per thousand yen9 and a parts per thousand yen20, respectively. Median follow-up was 47 months (IQR:70). In multivariable analyses that adjusted for the standard clinicopathologic factors, higher LN yield was associated with a decreased risk of disease recurrence (continuous: HR = 0.996, p = 0.05; 3rd vs 1st tertile: HR = 0.853, p = 0.048; cutoff a parts per thousand yen20: HR = 0.851, p = 0.032). In the subgroups of patients with muscle-invasive UCB or those with a parts per thousand yen9 LN removed, LN yield was not associated with outcomes (p values > 0.05). In this large multicenter cohort of patients with node-negative UCB, higher nodal yield improved recurrence-free survival when all patients were analyzed. Patients with a high LN yield (a parts per thousand yen20 LN removed or 3rd tertile) had the largest benefit. The lack of prognostic significance of LN yield in patients with muscle-invasive UCB or those stratified by 9 LNs removed suggests that this effect is weak. Further prospective studies are needed to help identify preoperatively the optimal template for each patient. To determine whether the number of lymph nodes (LNs) examined is associated with outcomes in patients without nodal metastasis after radical cystectomy (RC). We retrospectively analyzed data from 4,188 patients treated at 12 centers with RC and pelvic lymphadenectomy without neo-adjuvant chemotherapy for urothelial carcinoma of the bladder (UCB). Outcomes of patients without LN metastasis (n = 3,088) were examined according to the LN yield analyzed as continuous variable, tertiles, and using the cutoffs of a parts per thousand yen9 and a parts per thousand yen20. The median nodal yield was 18 (range 1-123; IQR:20). A total of 2591 (84 %) and 1445 (47 %) patients had a LN yield a parts per thousand yen9 and a parts per thousand yen20, respectively. Median follow-up was 47 months (IQR:70). In multivariable analyses that adjusted for the standard clinicopathologic factors, higher LN yield was associated with a decreased risk of disease recurrence (continuous: HR = 0.996, p = 0.05; 3rd vs 1st tertile: HR = 0.853, p = 0.048; cutoff a parts per thousand yen20: HR = 0.851, p = 0.032). In the subgroups of patients with muscle-invasive UCB or those with a parts per thousand yen9 LN removed, LN yield was not associated with outcomes (p values > 0.05). In this large multicenter cohort of patients with node-negative UCB, higher nodal yield improved recurrence-free survival when all patients were analyzed. Patients with a high LN yield (a parts per thousand yen20 LN removed or 3rd tertile) had the largest benefit. The lack of prognostic significance of LN yield in patients with muscle-invasive UCB or those stratified by 9 LNs removed suggests that this effect is weak. Further prospective studies are needed to help identify preoperatively the optimal template for each patient.
dcterms:title
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?
skos:prefLabel
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?
skos:notation
RIV/00064203:_____/12:8135!RIV13-MZ0-00064203
n14:predkladatel
n15:ico%3A00064203
n3:aktivita
n9:I
n3:aktivity
I
n3:cisloPeriodika
6
n3:dodaniDat
n17:2013
n3:domaciTvurceVysledku
n16:9308466
n3:druhVysledku
n4:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
131845
n3:idVysledku
RIV/00064203:_____/12:8135
n3:jazykVysledku
n10:eng
n3:klicovaSlova
Bladder cancer; Survival; Recurrence; Radical cystectomy; Lymph node; Transitional cell carcinoma; invasive bladder-cancer; transitional-cell carcinoma; lymph-nodes; pelvic lymphadenectomy; prostate-cancer; dissection; standardization; prognosis; survival; number
n3:klicoveSlovo
n5:Recurrence n5:prostate-cancer n5:standardization n5:Lymph%20node n5:lymph-nodes n5:transitional-cell%20carcinoma n5:Bladder%20cancer n5:number n5:Survival n5:dissection n5:Radical%20cystectomy n5:Transitional%20cell%20carcinoma n5:survival n5:pelvic%20lymphadenectomy n5:prognosis n5:invasive%20bladder-cancer
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[49D3EC57795C]
n3:nazevZdroje
World Journal of Urology
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
24
n3:rokUplatneniVysledku
n17:2012
n3:svazekPeriodika
30
n3:tvurceVysledku
Chun, FK Karakiewicz, PI Lotan, Y. Bastian, PJ Merseburger, AS Kamat, A. M. Kassouf, W. Fradet, Y. Svatek, RS Fritsche, H. M. Rink, M. Fitzgerald, J. P. Tagawa, ST Green, D. A. Daneshmand, S. Novara, G. Xylinas, E. Hansen, J. Scherr, DS Tilki, D. Trinh, QD Volkmer, B. G. Shariat, SF Babjuk, Marek
n3:wos
000311793500012
s:issn
0724-4983
s:numberOfPages
8